Cullinan Oncology Inc

NASDAQ:CGEM  
16.24
-0.95 (-5.53%)
Earnings Announcements

Cullinan Oncology Provides Corporate Update And Reports Q3 2021 Financial Results

Published: 11/09/2021 11:52 GMT
Cullinan Oncology Inc (CGEM) - Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results.
Cullinan Oncology Inc - Qtrly Research and Development Expenses $12.7 Million Versus $9.9 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.